Noveome: Noveome closes on $20.7M, halfway to $40M goal
Noveome, developer of a treatment for rare disease impacting premature infants, passes halfway mark in $40.2M funding round.
Read full article »
Noveome is a Pennsylvania-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of inflammatory and neurological disorders.
Read more